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Abstract 
Aims/hypothesis 
Hyperlipidaemia is an independent risk factor for the progression of diabetic nephropathy, but its molecular 
mechanism remains elusive. We investigated in mice how diabetes and hyperlipidaemia cause renal lesions 
separately or in combination, and the involvement of toll-like receptor 4 (TLR4) in this process. 
Methods 
Diabetes was induced in wild-type (WT) and Tlr4 knockout (KO) mice by intraperitoneal injection of 
streptozotocin (STZ). At 2 weeks after STZ injection, normal diet was substituted with high-fat diet (HFD). 
Functional and histological analysis was carried out 6 weeks later. 
Results 
As compared to treatment with STZ or HFD alone, treatment of WT mice with both STZ and HFD markedly 
aggravated nephropathy, as indicated by increase in albuminuria, mesangial expansion, and infiltration of 
macrophages and upregulation of pro-inflammatory and extracellular matrix-associated gene expression in 
glomeruli. In Tlr4 KO mice, addition of HFD to STZ had almost no effects as to above parameters. Protein 
expression of S100a8, a potent ligand for Tlr4, was abundantly observed in macrophages infiltrating STZ-HFD 
WT glomeruli and in glomeruli of diabetic nephropathy patients. High glucose and fatty acid treatment 
synergistically upregulated S100a8 gene expression in macrophages from WT mice, but not from KO. As putative 
downstream targets of Tlr4, phosphorylation of Irf3 was enhanced in kidneys of WT mice co-treated with STZ 
and HFD. 
Conclusions/interpretation 
Activation of S100a8/Tlr4 signaling was elucidated in an animal model of diabetic glomerular injury accompanied 
with hyperlipidaemia, which may provide novel therapeutic targets in progressive diabetic nephropathy. 
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Abbreviations: ESRD, end-stage renal disease; HFD, high fat diet; KO, knockout; ND, normal diet; nSTZ, 
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Introduction 
Diabetic nephropathy is one of the most prevalent causes of end-stage renal disease (ESRD) [1]. Despite progress 
in pharmacological strategies to control diabetes, hypertension and other metabolic abnormalities, the number of 
patients entering into the stage of ESRD due to diabetic nephropathy remains extremely large, and development of 
new classes of treating reagents is expected eagerly [2]. During recent decades, the pathophysiology of diabetic 
nephropathy is becoming complex and serious because of coexisting life-style-related disorders such as 
hyperlipidaemia, hypertension and obesity [3]. In fact, hyperlipidaemia is an independent risk factor for the 
progression of diabetic nephropathy both in type 1 and type 2 diabetes [4, 5], but the underlying molecular 
mechanism remains elusive [6].  
 Toll-like receptors (TLRs) are a family of receptors playing a critical role in the innate immune system 
by activating proinflammatory signaling pathways in response to molecular patterns synthesized by 
microorganisms [7]. TLR4, one of the best-characterized TLRs, binds with lipopolysaccharide from 
gram-negative bacterial cell walls and with several endogenous ligands [7]. TLR4 also plays an important role in 
various kidney disorders, such as glomerulonephritis, renal ischemia and diabetic tubular inflammation [8-13], but 
the role of TLR4 in diabetic glomelular injury or hyperlipidaemia-induced kidney damage remains largely 
unknown. 
 In the current study, TLR4 and its novel endogenous ligand S100A8 emerged as candidate molecules 
involved in the progression of diabetic nephropathy by our microarray analysis performed in two different types 
of diabetic mouse models. Furthermore, we examined the effects of high-fat diet (HFD) feeding on streptozotocin 
(STZ)-induced diabetes in Tlr4 knockout (KO) and wild-type (WT) mice in order to elucidate the mechanism for 
the progression of diabetic nephropathy caused by hyperlipidaemia.
Methods 
Experimental animals 
Male Tlr4 KO [14] and WT mice with C57BL/6J genetic background were studied. For generation of a mouse 
model of diabetes complicated with hyperlipidaemia, 8-week-old mice were intraperitoneally injected with STZ 
(100mg/kg body weight in citrate buffer, pH 4.0; Sigma-Aldrich, St Louis, MO, USA) or vehicle for 3 consecutive 
days. After 2 weeks, normal diet (ND; NMF, 14.7 kJ/g [3.5 kcal/g], 13% of energy as fat; Oriental Yeast Co., 
Tokyo, Japan) was substituted with HFD (D12451, 19.7 kJ/g [4.7 kcal/g], 45% of energy as fat; Research Diets, 
New Brunswick, NJ, USA) in subgroups of animals, and all were killed for analysis at 8 weeks after STZ 
treatment. In another set of experiments, 8-week-old male db/db mice (in BKS genetic background; Japan Clea, 
Tokyo, Japan) were randomly assigned into ND or HFD (D12492, 21.8 kJ/g [5.2 kcal/g], 60% of energy as fat; 
Research Diets) groups and followed for 4 weeks. All animal experiments were conducted in accordance with the 
Guidelines for Animal Research Committee of Kyoto University Graduate School of Medicine. 
Human biopsy samples 
Human kidney samples obtained at renal biopsy carried out in our department were used for 
immunohistochemistry. The human study protocol was approved by the Ethical Committee on Human Research of 
Kyoto University Graduate School of Medicine. All participants gave written informed consent. 
Measurement of metabolic parameters 
Metabolic parameters were measured as described previously [15, 16]. Briefly, blood pressure was measured by 
indirect tail-cuff method (Muromachi Kikai, Tokyo, Japan). Urine samples were collected with metabolic cages, 
and urinary albumin was measured with competitive ELISA (Exocell, Philadelphia, PA, USA). Serum and urinary 
creatinine levels were assayed by enzymatic method (SRL, Tokyo, Japan) [17]. Plasma glucose, triacylglycerol 
(TG) and total cholesterol levels were measured at ad libitum-fed conditions using enzymatic method (Wako Pure 
Chemicals, Osaka, Japan). Plasma insulin levels were measured by enzyme immunoassay (Morinaga, Tokyo, 
Japan). For measurement of tissue TG contents, lipids were extracted with isopropyl alcohol/heptane (1:1 
vol./vol.) from frozen kidney samples. After evaporating the solvent, lipids were resuspended in 99.5% ethanol 
and TG contents were measured as described above. 
Real-time quantitative RT-PCR 
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and cDNA in each sample was 
synthesized by High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) from 
mouse kidneys and glomeruli that were isolated by graded sieving method [18, 19]. TaqMan real-time PCR was 
performed using Premix Ex Taq (Takara Bio, Otsu, Japan) and StepOnePlus Real Time PCR System (Applied 
Biosystems, Foster City, CA, USA). See electronic supplementary material (ESM) Table 1 for primer and probe 
sequences. Expression levels of all genes were normalized by Gapdh (internal control) levels. Mean expression 
level in whole kidney of WT, non-treated control mice was arbitrarily defined as 1.0. 
Histological analysis 
Periodic acid–Schiff (PAS) staining of mesangial area and immunohistochemistry of S100a8 (requiring antigen 
retrieval by citrate buffer) and Mac-2 (or Lgals3)[18] were carried out using kidney sections (thickness 4 µm) 
fixed with 4% buffered paraformaldehyde. Nuclei were counterstained with hematoxylin. All primary antibodies 
used in this study are shown in ESM Table 2. For double staining, primary antibody for S100a8 was visualized 
with DyLight-conjugated secondary antibody (Takara Bio, Otsu, Japan). Immunofluorescence of Podocin (or 
Nphs2) was performed with snap frozen cryostat sections (4 µm), pretreated with cold acetone and 0.1% 
Triton-X100, and with primary and FITC-labelled secondary antibodies. Photos were taken by a fluorescence 
microscope (IX81-PAFM; Olympus, Tokyo, Japan). Mesangial and Podocin-positive areas of more than 10 
glomeruli from the outer cortex were measured quantitatively to obtain an average for each mouse using 
MetaMorph 7.5 software (Molecular Devices, Downingtown, PA, USA). Formalin-fixed, snap-frozen sections (10 
µm) were stained with Oil Red O to evaluate lipid droplet-positive areas. 
Microarray analysis 
Two different types of diabetic model mice were employed for microarray analysis. Male A-ZIP/F-1 heterozygous 
transgenic mice and control male FVB/N littermates were used at 10 months of age, when A-ZIP/F-1 mice 
exhibited diabetic nephropathy with massive proteinuria [20]. The other model was STZ-induced, 
insulin-dependent, diabetic C57BL/6J male mice (Japan Clea, Tokyo, Japan) whose diabetes was induced at 9 
weeks of age by single intraperitoneal injection of STZ (180 mg/kg) and analyzed 8 weeks later. We essentially 
followed the procedures described in detail in the GeneChip Eukaryotic Target Preparation & Hybridization 
Manual (Affymetrix, Santa Clara, CA, USA). In brief, cDNA was synthesized and biotin-labelled cRNA was 
produced through in vitro transcription labelling Kit (Affymetrix). Fragmented cRNA was hybridized to 
GeneChip Mouse Genome 430 2.0 Array (Affymetrix) at 45°C for 16 h. The samples were washed and stained 
according to the manufacturer’s protocol on GeneChip Fludisc Station 450 (Affymetrix) and scanned on 
GeneChip Scanner 3000 (Affymetrix).  
PCR Array analysis 
To eliminate contaminating genomic DNA, total RNA extracted from kidney samples was purified using RNeasy 
Mini Kit (QIAGEN Sciences, Maryland, MD, USA). First-strand cDNA was synthesized from total RNA using 
RT2 first-strand kit (SABiosciences, Frederick, MD, USA). Mouse TLR-signaling pathway RT2 Profiler PCR 
plate (PAMM-018, SABiosciences) and StepOnePlus were used for amplification of cDNA. 96-well plates 
containing gene-specific primer sets for 84 relevant TLR pathway genes, 5 housekeeping genes, and 2 negative 
controls were used. The cycle threshold (CT) was determined for each sample and normalized to the average CT 
of the 5 housekeeping genes. Comparative delta-CT method (SABiosciences) was used to calculate relative gene 
expression. 
Western blot analysis 
Proteins extracted from kidney samples were separated by SDS-PAGE, transferred onto PVDF membranes, 
incubated with primary antibodies and detected with peroxidase-conjugated secondary antibodies and 
chemiluminescence [19]. Gapdh was used as an internal control.  
Cultured macrophages 
Palmitate (Sigma-Aldrich) was solubilized in ethanol, and combined with fatty acid-free, low endotoxin, bovine 
serum albumin (Sigma-Aldrich) at a molar ratio of 10: 1 in serum-free medium. Polymyxin B (10 µg/ml, Nacalai 
Tesque, Kyoto, Japan) was added to each well to minimize contamination of endotoxin. Bone marrow-derived 
macrophages were generated from mice as described previously [21]. Briefly, following lysis of red blood cells, 
bone marrow cells were resuspended in medium containing 20% fetal calf serum and 50 ng/ml recombinant 
human M-CSF, and cultured at 37°C in 5% CO2 atmosphere. On day 6, medium was replaced with fresh one 
containing 5.6 mM or 25 mM glucose. On day 7, macrophages were incubated with palmitate or vehicle for 24 h. 
Total RNA from cells was extracted with RNeasy Mini Kit, and mRNA expression levels of S100a8 and Tlr4 were 
determined by TaqMan real-time RT-PCR. 
Statistical analysis 
Data are expressed as means±SEM. Differences between multiple groups were assessed by two-way factorial 
ANOVA with Bonferroni’s post test. Comparison between two groups was carried out by unpaired Student’s t test. 





Changes of metabolic parameters and albuminuria in wild-type diabetic mice given fat-rich diet 
Metabolic parameters of non-STZ (nSTZ)-HFD, STZ-ND, STZ-HFD and control nSTZ-ND groups in WT mice 
are shown in Table 1. HFD treatment (as compared to ND) in nSTZ mice caused significant elevation of body 
weight, plasma glucose, insulin, TG and total cholesterol levels. STZ treatment (compared to nSTZ) in ND mice 
caused significant body weight loss and significant elevation of plasma glucose, TG and total cholesterol levels. 
Treatment of STZ mice with HFD resulted in large exacerbation of hypertriglyceridaemia (by 2.3-fold) without 
significant changes in other, above-mentioned parameters (Table 1). Consistently, renal lipid deposition in 
STZ-HFD mice was markedly increased as compared to STZ-ND mice (Fig. 1a, b). Blood pressures were not 
significantly different among the four treatment groups (Table 1).  
Concerning albuminuria, one of the representative abnormalities which characterize diabetic 
nephropathy [2], albumin excretion in STZ-ND was elevated by 2.3-fold at 8 weeks as compared to nSTZ-ND 
mice (Fig. 1c). Addition of HFD to STZ mice further enhanced albuminuria approximately by two-fold. To 
investigate podocyte injury, we investigated whether Podocin protein expression is decreased in glomeruli of 
STZ-HFD mice [19]. Glomerular Podocin expression was significantly reduced in STZ-ND compared to 
nSTZ-ND and its expression was lowest in STZ-HFD (Fig. 1e, f). Also in obese, type 2 diabetic db/db mice, 
albuminuria was exaggerated by HFD (ESM Fig. 1). To summarize, combinatory treatment of WT mice with HFD 
and STZ resulted in marked enhancement of hypertriglyceridaemia, renal lipid deposition, podocyte damage and 
albumin excretion. 
Gene expression analysis of pro-inflammatory and extracellular matrix-associated genes in whole kidney and 
glomeruli and histological examination 
We measured mRNA levels of pro-inflammatory and extracellular matrix (ECM)-associated genes both in whole 
kidney and isolated glomeruli (Fig. 2, ESM Table 3). The former genes included Mcp1 (or Ccl2, encoding 
monocyte chemoattractant protein-1), F4/80 (Emr1), Cd68, Tnfa (tumor necrosis factor α), Pai1 (plasminogen 
activator inhibitor-1) and Il1b (interleukin-1 β); and the latter were Tgfb1 (transforming growth factor β1), Fn 
(fibronectin), Col4a3 (type IV collagen alpha 3 chain), Ctgf (connective tissue growth factor) and Mmp2 (matrix 
metalloproteinase 2). We found that expression levels of these genes in glomeruli and whole kidney were mildly 
elevated in WT STZ-ND compared to WT nSTZ-ND mice, in general (Fig. 2, ESM Table 3). Furthermore, gene 
expression levels were further upregulated in WT STZ-HFD animals. Of note, differences between nSTZ-HFD 
and nSTZ-ND groups were negligible (Fig. 2). Histological analysis also showed that Mac-2+-macrophage 
infiltration into glomeruli (Fig. 3a) and renal interstitium (ESM Fig. 2) and glomerular mesangial expansion (Fig. 
3b) in STZ-HFD were markedly larger than those in STZ-ND mice. 
Screening of candidate genes involved in pathogenesis of diabetic nephropathy 
To identify candidate molecules potentially involved in the pathophysiology of diabetic nephropathy, we analyzed 
gene expression profiles of diabetic mouse glomeruli by microarray (ESM Table 4). We decided to compare 2 
types of diabetic nephropathy from STZ-induced and A-ZIP/F-1 lipoatrophic diabetes mice. We selected 
commonly regulated genes to minimize interference from renal toxicity of STZ, from genetic background [22] and 
from direct insulin or leptin target molecules [23]. List of genes commonly upregulated in these 2 models included 
pro-inflammatory and ECM-associated genes and also ones encoding TLRs (ESM Table 4). Since pairs of cell 
surface receptors and their ligands provide attractive seeds for future therapeutic targets, we focused upon Tlr4, 
whose glomerular expression levels were elevated by 1.7-fold by STZ and 5.8-fold in A-ZIP/F-1 as compared to 
each control by microarray. We further examined the expression of molecules reported to be endogenous ligands 
for Tlr4 [7], and identified S100a8 (or myeloid-related protein 8, Mrp8) and S100a9 (Mrp14) [24], whose 
glomerular expressions were commonly upregulated in 2 models of diabetic nephropathy by microarray (ESM 
Table 4). Upregulation of Tlr4 and S100a8 gene expression in glomeruli of STZ and A-ZIP/F-1 mice were 
confirmed by quantitative RT-PCR (ESM Fig. 3a, b). Moreover, in STZ-HFD mice, expression of these genes was 
further potentiated as compared to other groups such as STZ-ND and nSTZ-HFD, especially in glomeruli (Fig. 4a), 
but not in whole kidney (ESM Fig. 4). On the other hand, expressions of other endogenous ligands for Tlr4, such 
as Hmgb1 (high mobility group box 1), were not largely and simultaneously upregulated in STZ and A-ZIP/F-1 
mice as compared to their respective controls by microarray (ESM Table 4) or by quantitative RT-PCR (ESM Fig. 
3c, d).  
Expression of S100a8 protein in diabetic kidney 
We performed immunohistochemical analyses of S100a8 protein in the kidneys both in STZ-HFD mice and 
human biopsy samples. In mice, abundant expression of S100a8 protein, in a punctate pattern, was observed 
predominantly in glomeruli of WT STZ-HFD mice, while S100a8 expression was much less in glomeruli of 
nSTZ-ND, nSTZ-HFD and STZ-ND groups (Fig. 4b, ESM Fig. 5). S100a8 protein was also expressed in the 
interstitium of STZ-HFD mice but less abundantly compared to glomerular expression. Double immunostaining 
revealed that 86% of S100a8 signals co-localized with macrophage marker Mac-2 in glomeruli of STZ-HFD mice 
(Fig. 4c). In humans, S100A8 was abundantly expressed in glomeruli of patients with diabetic nephropathy, but 
not obviously in glomeruli of minor glomerular abnormality or minimal change nephrotic syndrome cases (Fig. 
5).  
Effects of Tlr4 defect upon STZ-HFD mice and upon bone marrow-derived macrophages 
To elucidate a functional role played by Tlr4 in the progression of diabetic nephropathy accelerated by 
diet-induced hyperlipidaemia, we investigated effects of STZ and HFD in Tlr4 KO mice. In baseline nSTZ-ND 
conditions, KO mice showed significantly heavier body weights compared to WT mice, which was paralleled by 
mildly elevated plasma levels of glucose, insulin, TG and total cholesterol in KO mice (Table 1). Plasma glucose 
levels in KO nSTZ-HFD mice were slightly lower compared to their WT counterparts. These findings are 
consistent with previous observations indicating that, as compared to WT mice, Tlr4 KO mice are prone to 
accumulation of fat but resistant to development of insulin resistance when challenged by HFD [25, 26]. When 
STZ-HFD conditions were compared between KO and WT mice, the levels of plasma glucose and total 
cholesterol and renal lipid deposition were similar among the genotypes and plasma TG levels tended to be higher 
in KO than WT mice (Table 1, Fig. 1b). On the other hand, exacerbation of albuminuria and suppression of 
glomerular Podocin protein expression resulting from HFD treatment in WT STZ mice were all largely blunted in 
KO STZ animals (Fig. 1c-f). Additionally, infiltrated macrophage counts in glomeruli and renal interstitium and 
mesangial expansion were remarkably smaller in KO STZ-HFD than those in WT STZ-HFD mice (Fig. 3, ESM 
Fig. 2). Furthermore, upregulation of pro-inflammatory (Mcp1 and Pai1), pro-fibrotic (Fn and Ctgf), S100a8 and 
S100a9 gene expression and S100a8-positive cell counts caused by HFD treatment in glomeruli of WT STZ mice 
were almost completely abolished in KO STZ mice (Fig. 2, Fig. 4a, b, ESM Fig. 5). These findings indicate that, 
despite similar degrees of metabolic abnormalities caused by diabetes and hyperlipidaemia, Tlr4 KO developed 
much less severe renal lesions as compared to WT mice.  
With regard to comparison between WT and Tlr4 KO mice treated with STZ alone (STZ-ND mice), 
urinary albumin excretion (Fig. 1c, d), glomerular Podocin expression (Fig. 1e, f), glomerular gene expression of 
Mcp1, Pai1, Fn, Ctgf, S100a8 and S100a9 (Fig. 2, Fig. 4a), and glomerular macrophage infiltration (Fig. 3a) were 
all similar among two genotypes, suggesting that Tlr4 does not strongly participate in early and mild changes of 
diabetic nephropathy. Concerning HFD alone treatment (nSTZ-HFD mice), there was no significant difference in 
urinary albumin excretion and glomerular Podocin expression between WT and KO mice (Fig. 1c-f), while 
glomerular S100a9 gene expression (Fig. 4a) and glomerular macrophage infiltration (Fig. 3a) were significantly 
attenuated in KO as compared to WT, suggesting that treatment solely with HFD significantly activated 
circulating macrophages in WT mice but Tlr4-mediated signal in nSTZ-HFD mice was not sufficient to cause 
functional changes in glomeruli. 
 To gain insights concerning how combination of diabetes and hyperlipidaemia resulted in markedly 
enhanced migration of macrophages into glomeruli, we examined bone marrow-derived macrophages. We focused 
attention upon expression of a potent Tlr4 ligand, S100a8 [24]. Treatment of WT macrophages with a fatty acid, 
palmitate, induced S100a8 mRNA upregulation when the cells were cultured in high glucose conditions, but 
upregulation was not observed under low glucose conditions (Fig. 6a). Furthermore, induction of S100a8 
expression by palmitate in high glucose-treated macrophages did not occur in cells from Tlr4 KO animals (Fig. 
6b). High glucose treatment slightly increased Tlr4 expression in WT macrophages (Fig. 6c). 
Tlr4 signaling in the kidney of STZ-HFD model 
To examine Tlr4-downstream signaling cascade, we performed Western blot analyses of key adaptor proteins and 
transcription factors which have been reportedly classified into Myd88-dependent, Trif (TIR-domain-containing 
adapter-inducing interferon-β)-dependent or common pathways (Fig. 7a) [7], using whole kidney lysate. 
Treatment of WT STZ mice with HFD was associated with increased phosphorylation of Ikb (inhibitor κB) and 
Jnk (c-Jun N-terminal kinase) in common pathway, and with increased phosphorylation of Irf3 (interferon 
regulatory factor 3) in Trif-dependent pathway, but neither with increased protein expression of Traf6 (TNF 
receptor-associated factor 6) nor with increased phosphorylation of Irak (interleukin-1 receptor–associated kinase) 
in Myd88-dependent pathway (Fig. 7b, c). PCR-array analysis, which allows simultaneous evaluation of relevant 
genes involved in the signaling cascades of Tlr1-Tlr9, confirmed that in WT STZ-HFD kidneys, Trif-dependent 
pathway-inducible genes (Cxcl10, Ifnb1 [encoding interferon β1] and Cd80) and common pathway-inducible 
genes (Mcp1) were highly upregulated, but genes involved in Myd88-dependent pathway (Cd14, Ly96 [encoding 
MD-2], and Traf6) were not changed compared to WT STZ-ND kidneys (ESM Table 5). Furthermore, disruption 
of Tlr4 gene markedly blocked the activation of putative Tlr4 downstream signaling cascade in STZ-HFD mice 
(Fig. 7b, c, ESM Table 5). 
Discussion   
In the present study, we have revealed that combinatory treatment of WT mice with STZ and HFD synergistically 
aggravated renal lesions, which were indicated by enhancement of albuminuria, macrophage infiltration, 
mesangial expansion and pro-inflammatory/ECM-associated gene induction in glomeruli. These changes were 
accompanied with upregulation of a Tlr4 ligand S100a8 and activation of putative Trif-dependent pathway 
downstream of Tlr4. In Tlr4 KO mice, addition of HFD to STZ had almost no effects upon kidney damage, 
suggesting that Tlr4 plays an important role in exacerbation of diabetic nephropathy by hyperlipidaemia.  
Of note, treatment with STZ alone caused similar and mild renal changes in WT and KO mice, 
suggesting that Tlr4 signal may not significantly participate in the onset of diabetic nephropathy at 8 weeks after 
STZ injection [13]. On the other hand, WT mice fed with HFD (nSTZ-HFD) exhibited significantly larger S100a9 
gene expression and more macrophage infiltration in glomeruli as compared to KO mice, but these effects were 
not reflected to differences in other parameters of renal lesions, suggesting that macrophage activation in 
nSTZ-HFD mice may require longer observation periods than ones in this study to be functionally relevant. 
 Here, to study the effects of HFD upon diabetes, we took advantage to use lean, type 1 diabetes model 
to avoid complexity due to alteration of insulin resistance and fat accumulation by HFD or by Tlr4 gene disruption 
in type 2 diabetes model [19, 20]. HFD-induced and hypertriglyceridemia-associated renal injury observed in this 
study may have been caused through activation of Tlr4 by free fatty acids [25, 26], oxidized LDL [27], or TG-rich 
lipoproteins [6]. Previous studies have proposed that, by direct lipotoxicity upon tubular epithelial cells, 
diet-induced obesity alone is sufficient to cause inflammatory and fibrotic changes in the whole kidney 
preparations through expression of Cd36 and Srebp1c (sterol regulatory element-binding protein-1c) [28-30]. In 
the present study, however, treatment of WT mice solely with HFD resulted in very mild renal lesions, likely 
because we used diet with less fat content and studied for a shorter period of time compared to earlier reports 
[28-30]. Furthermore, HFD increased glomerular Cd36 mRNA expression but STZ-induced diabetes reduced it, 
and glomerular Srebp1c expression was decreased both by HFD and STZ (ESM Fig. 6), indicating that 
HFD-induced exacerbation of diabetic nephropathy cannot be explained by upregulation of Cd36 or Srebp1c.  
S100a8 forms a heterodimer with S100a9, and the complex is one of the most powerful, endogenous 
ligands for Tlr4, which is essential in full activation of macrophages and other leukocytes, by a positive feedback 
loop, during endotoxin-induced shock and vascular and autoimmune disorders [24, 31, 32]. Tlr4 signaling also 
plays an important role in the development of various kidney diseases, yet the role of Tlr4 in diabetic 
glomerulopathy or hyperlipidaemia-induced kidney damage have remained to be elucidated [8-13]. Recently, 
Burkhardt et al. and Bouma et al. reported that serum S100A8/A9 complex concentrations were elevated in 
patients with diabetes [33, 34]. In our study, S100a8 protein was abundantly expressed in glomeruli of mice given 
STZ and HFD and also in glomeruli of patients with diabetic nephropathy, and was mainly expressed by 
macrophages. Furthermore, we found that high glucose and free fatty acid treatments, when combined, markedly 
upregulated S100a8 expression in WT macrophages, but not in Tlr4 KO macrophages. These findings suggest that 
expression of S100a8 is not just an indicator of systemic inflammation but may play a pathogenic role in 
deterioration of diabetic nephropathy. Functional analysis of S100a8 protein expression in diabetic mice is 
currently underway in our lab. On the other hand, candidate Tlr4-expressing cells in diabetic kidney include 
macrophages, podocytes, mesangial and tubular epithelial cells [8, 9]. So far, we could not obtain reliable findings 
by immunohistochemistry using commercially-available antibodies for Tlr4, and are now trying other methods. Of 
note, upregulation of S100a8 gene expression by HFD in STZ mice was also observed in the liver and aorta, 
suggesting that effects of these treatments are not specifically targeted to the kidney but are systemic (ESM Fig. 6). 
Hmgb1 is one of endogenous ligands of Tlr4 [9], and Ager (advanced glycosylation end product-specific receptor 
or RAGE) is one of S100a8 receptors so far identified [35]. Although mRNA expressions of these molecules in 
glomeruli were not upregulated in diabetic mice of this study (ESM Fig. 3, ESM Table 4), we cannot exclude a 
possibility that they are involved in hyperlipidaemia-induced renal injury. 
Macrophage has been presumed to be a critical mediator of diabetic nephropathy [36-38], and blockade of 
the MCP-1/CC chemokine receptor 2 system in diabetic mice leads to reduced albuminuria, mesangial expansion 
and macrophage infiltration [39-42]. Secretory factors from macrophages may cause histological and functional 
changes in glomeruli. For instance, Tgfb1 (transforming growth factor β1) and Mcp1, induced in surrounding 
cells by or secreted directly by activated macrophages, have been shown to upregulate Ctgf expression [43] and 
increase albumin permeability in cultured podocytes [44-46], and we have recently reported that overexpression 
of Ctgf specifically in podocytes is sufficient to worsen diabetic nephropathy [19].  
 Downstream signaling of Tlr4 have been divided into Myd88-dependent and Trif–dependent pathways, 
and they lead to early- and late-phase Nfkb (NF-κB) activation, respectively [7]. In addition, endocytosed Tlr4 
activates Trif-dependent pathway [47]. It is interesting if pathologically accumulated lipids in endosomes of 
macrophages can cause chronic inflammation via Trif-dependent pathway in the kidney of STZ-HFD mice. Here, 
in STZ-HFD kidneys, we observed increase of Irf3 protein phophophorylation and Cxcl10, Ifnb1 and Cd80 
mRNA expression reported to be in Trif-dependent pathway, but experiments blocking Trif activity is required to 
demonstrate Trif-dependency of the process. 
In conclusion, we have elucidated a novel mechanism of hyperlipidaemia-induced renal damage in 
diabetic conditions in a Tlr4-dependent manner, which appears to involve the activation of S100a8/Tlr4 signaling 
pathway in glomeruli. Further investigation is required to see whether this signaling cascade is relevant in the 
progression of nephropathy in diabetic patients. 
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Table 1 
Metabolic data of WT and Tlr4 KO mice at 8 weeks after STZ injection 
Data are means±SEM. Blood was collected at ad libitum feeding conditions. nSTZ, non-STZ; ND, normal diet; 
HFD, high fat diet. *p<0.05 vs. nSTZ-ND. #p<0.05 vs. nSTZ-HFD. †p<0.05 vs. STZ-ND. $p<0.05 vs. similarly 
treated group of WT. Two symbols, p<0.01; three symbols, p<0.001. 
 
                    WT                                              KO                          
 nSTZ-ND nSTZ-HFD STZ-ND STZ-HFD nSTZ-ND nSTZ-HFD STZ-ND STZ-HFD 
Number of animals 
 
6 4 8 11 4 4 5 8 
Body weight (g) 
 
27.7±1.0 33.7±0.5** 20.0±0.9** 22.1±0.5**### 34.9±2.4$ 39.6±1.4$ 22.0±1.3** 23.3±0.6***### 
Blood pressure (mmHg)         
    Systolic 101±2 104±2 98±1 100±1 103±2 103±2 96±1* 101±2 
    Diastolic 
 
56±2 57±3 52±2 56±2 55±1 57±2 50±1* 53±1 
Kidney weight (%body 
weight) 
 
0.5±0.0 1.0±0.0** 1.7±0.1** 1.8±0.1**### 1.0±0.1$$$ 2.2±0.2***$$ 1.9±0.2*** 1.9±0.1*** 
Plasma glucose (mmol/l) 
 
9.5±1.6 14.0±0.4* 40.0±3.9** 32.9±1.8**# 10.4±1.1 12.7±2.3 36.0±7.7* 31.8±2.3***## 
HbA1c (%) 
 
3.4±0.1 5.3±0.1** 9.6±0.6** 9.9±0.5**# 3.0±0.3 4.9±0.2** 9.4±1.1** 10.3±0.3***### 
Plasma insulin (pmol/l) 
 




0.99±0.02 1.20±0.03** 2.36±1.01* 5.48±1.56*# 1.74±0.32 1.42±0.11 3.12±1.56 7.64±1.58**## 
Plasma total cholesterol 
(mmol/l) 
 
1.5±0.4 3.4±0.3* 5.1±0.8* 5.2±0.5** 1.9±0.4 3.4±0.2* 3.8±0.6* 5.9±0.4**##† 
Serum creatinine (µmol/l) 
 
8.0±1.8 8.8±0.1 10.6±0.9 15.9±5.3 8.8±0.1 8.0±0.1$$ 10.6±1.8 8.0±0.1 
         
Figure legends 
Fig. 1 
Treatment of STZ diabetic mice with high fat diet (HFD) worsens renal injury in WT but not in Tlr4 KO mice. (a, 
b) Addition of HFD to STZ mice causes similar degrees of Oil Red O+-lipid droplet deposition in WT (open bars) 
and KO mice (solid bars) at 16 weeks of age. Magnification, 4x. ND, normal diet. Data are means±SEM. n=5. 
***p< 0.001. (c) Time course of urinary albumin levels normalized with urinary creatinine levels in WT (c) and 
Tlr4 KO mice (d). Circles, nSTZ-ND; triangles, nSTZ-HFD; squares, STZ-ND; rhomboids, STZ-HFD. W, weeks 
after STZ injection. n=6-10. †p<0.05 vs. WT STZ-ND, $p<0.05 vs. WT STZ-HFD calculated by area under the 
curve. (e, f) Immunofluorescence analysis of glomerular Podocin expression. White bars, WT; black bars, KO. 
n=4-6. *p<0.05, **p<0.01, ***p<0.001. $p<0.05 for similarly treated KO vs. WT. 
Fig. 2 
Treatment with STZ and HFD synergistically upregulates inflammatory and extracellular matrix-associated gene 
expression in glomeruli of WT mice by real-time RT-PCR, but effects of HFD are largely blunted in Tlr4 KO mice. 
White bars, WT; black bars, KO. Data are means±SEM. n=4-11. *p<0.05, **p<0.01, ***p<0.001. 
Fig. 3 
Glomerular macrophage infiltration and mesangial matrix accumulation are markedly enhanced in WT mice 
co-treated with STZ and HFD, but not in Tlr4 KO mice. (a) Macrophage number per glomerular section 
determined by Mac-2 immunostaining (arrows). Magnification, 40x. Data are means±SEM. n=4-5. (b) Glomelular 
mesangial area determined by PAS staining (purple). Magnification, 20x. n=4-6. White bars, WT; black bars, KO. 
**p<0.01. ***p<0.001. $p<0.05, $$p<0.01 for similarly treated KO vs. WT. 
 
Fig. 4 
Glomelular expression of Tlr4, S100a8 and S100a9 mRNA and S100a8 protein is markedly upregulated in WT 
STZ-HFD but not in Tlr4 KO STZ-HFD mice, and S100a8 is predominantly expressed by glomerular 
macrophages in WT STZ-HFD mice. (a) Gene expression of Tlr4, S100a8 and S100a9 in glomeruli determined by 
real-time RT-PCR. White bars, WT; black bars, KO. Data are means±SEM. n=4-11. *p<0.05, **p<0.01. $p<0.05, 
$$p<0.01 for similarly treated KO vs. WT. (b) Glomerular S100a8 protein expression (brown) examined by 
immunohistochemistry. Magnification, 40x. (c) Localization Mac-2 (brown in Fig. 4c-1, pseudocolored with 
green in 4c-3, by immunohisochemistry), S100a8 (red in 4c-2 and 4c-3, by immunofluorescence) and their 
overlaps (yellow in 4c-3) in glomeruli of WT STZ-HFD mice. 
Fig. 5 
Expression of S100A8 (brown) is observed in glomeruli of patients with diabetic nephropathy by 
immunohistochemistry. (a) Minor glomerular abnormality. (b) Minimal change nephrotic syndrome. (c) Mild and 
(d) severe cases of diabetic nephropathy. 
Fig. 6 
S100a8 expression in bone marrow-derived macrophages (BMDM) is synergistically induced by high glucose and 
palmitate in a Tlr4-dependent manner. (a, b) S100a8 mRNA expression by real-time RT-PCR in BMDM from WT 
(a) and Tlr4 KO (b) mice cultured under low or high (100 or 450 mg/dl) glucose conditions, and effects of 
palmitate (10-200 µM). Data are means±SEM. n=6. (c) Tlr4 mRNA expression in WT BMDM. n=6. Open bars, 
WT low glucose; Solid bars, KO low glucose; chequered bars, high glucose conditions. *p< 0.05, **p< 0.01. 
 
Fig. 7 
Exacerbation of STZ-induced diabetic nephropathy by HFD is associated with increased phosphorylation of 
proteins involved in Trif-dependent and common pathways of Tlr4 signaling cascade in WT kidney but not in Tlr4 
KO kidney. (a) Schema describing known Tlr4 signaling cascade. Common pathway can be activated both 
through Myd88-dependent and Trif-dependent pathways. Key molecules analyzed in b are highlighted as elliptical 
objects. (b, c) Western blot analyses of Tlr4 signaling and quantitative evaluation. White bars, WT; black bars, KO. 
Data are means±SEM. n=4. *p<0.05, **p<0.01. $$p<0.01 for similarly treated KO vs. WT. 
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ESM Table 1 
Primer and probe sequences for real-time RT-PCR 
 
 




Gene Forward primer Reverse primer Probe 
Desmin 5'-AGAGCAGGATCAACCTTC-3' 5'-CTGACAACCTCTCCATCC-3' 5'-FAM-CCTTCTCTGCTCTCAACTTCCG-TAMRA-3' 
Mcp1 5'-TTGGCTCAGCCAGATGCA-3' 5'-CCAGCCTACTCATTGGGATCA-3' 5'-FAM-CCCCACTCACCTGCTACTCATTCA-TAMRA-3' 
F4/80 5'-TGGTGGTCATAATCTCTGCTTCTG-3' 5'-AGACAGGCCCCAGGAAACTC-3' 5'-FAM-CCCGTCTCTGTATTCAACCAGCAGCGATT-TAMRA-3' 
Cd68 5'-GCGGTGGAATACAATGTGTCC-3' 5'-TTGGCCCAAGGGAGCTTG-3' 5'-FAM-CGCCATGAATGTCCACTGTGCTGCCT-TAMRA-3' 
Tnfa 5'-AAGGCTGCCCCGACTACG-3' 5'-AGGTTGACTTTCTCCTGGTATGAG-3' 5'-FAM-AGGTTGACTTTCTCCTGGTATGAG-TAMRA-3' 
Pai1 5'-AAGGTCAGGATCGAGGTAAACG-3' 5'-GCCGAACCACAAAGAAAGG-3' 5'-FAM-GAGCGGCACAGTGGCGTCTTCCTCC-TAMRA-3' 
Tgfb1 5'-GACGTCACTGGAGTTGTACGG-3' 5'-GCTGAATCGAAAGCCCTGT-3' 5'-FAM-AGTGGCTGAACCAAGGAGACGGAA-TAMRA-3' 
Fn 5'-ATCATTTCATGCCAAGTT-3' 5'-TCGCACTGGTAGAAGTTCCA-3' 5'-FAM-CCGACGAAGAGCCCTTACAGTTCCA-TAMRA-3' 
COL4a3 5'-TGTGGATGCACGGTGTGTT-3' 5'-GTTCTCTTCACGGTGTGCTTGA-3' 5'-FAM-CCTTCCATCTCCTCCCTGACACCTTAGACT-TAMRA-3' 
Ctgf 5'-TTCCCGAGAAGGGTCAAGCT-3' 5'-TCCTTGGGCTCGTCACACA-3' 5'-FAM-CCTGGGAAATGCTGCAAGGAGTGG-TAMRA-3' 
Mmp2 5'-CCTGGTTTCACCCTTTCTGCT-3' 5'-CGAGCGAAGGGCATACAAA-3' 5'-FAM-CCCAGATACCTGCACCACCTTAACTGTTGC-TAMRA-3' 
Tlr4 5'-CTTCAGTGGCTGGATTTATC-3' 5'-GAGGTGGTGTAAGCCATG-3' 5'-FAM-CATGCCTTGTCTTCAATTGTTTCAA-TAMRA-3' 
S100a8 5'-ATCCTTTGTCAGCTCCGTCTTC-3' 5'-GGGCATGGTGATTTCCTTGTATATT-3' 5'-FAM-ATCTTTCGTGACAATGCCGTCTGAACTGGA-TAMRA-3' 
S100a9 5'-GAAGGAAGGACACCCTGACAC-3' 5'-TTTATGAGGGCTTCATTTCTCTTCTC-3' 5'-FAM-AAGGTTGCCAACTGTGCTTCCACCATT-TAMRA-3' 
Hmgb1 5'-GGACCCCAATGCACCCAAG-3' 5'-TCACCAATGGATAAGCCAGGATG-3' 5'-FAM-CCTCCTTCGGCCTTCTTCTTGTTCTGTTCT-TAMRA-3' 
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IHC, immunohistochemistry; IF, immunofluorescence; WB, Western blot. 
 
Antibody Species Antigen Company Method Corresponding Data
rabbit mouse Podocin Sigma-Aldrich, St Louis, MO, USA IF Fig. 1e, f
goat mouse S100a8 R&D systems, Minneapolis, MN, USA IHC Fig. 4b, c
rat monoclonal mouse Mac-2 Cedarlane, Burlington, Ontario, Canada IHC Fig. 4c
mouse monoclonal human S100A8 BMA Biomedicals, Rheinstrasse, Switzerland IHC Fig. 5
mouse monoclonal mouse pIkb Cell Signaling, Boston, MA, USA WB Fig. 7b, c
mouse monoclonal mouse pJnk Santa Cruz Biotechnology, Santa Cruz, CA, USA WB Fig. 7b
rabbit mouse tJnk Santa Cruz Biotechnology, Santa Cruz, CA, USA WB Fig. 7b
rabbit mouse pIrak Abcam, Cambridge, CA, UK WB Fig. 7b, c
rabbit mouse Traf6 MBL, Nagoya, Japan WB Fig. 7b
rabbit mouse pIrf3 Cell Signaling, Boston, MA,USA WB Fig. 7b, c
mouse monoclonal mouse Gapdh Santa Cruz Biotechnology, Santa Cruz, CA, USA WB Fig. 7b, c
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The gene expression levels divided by Gapdh expression levels in respective groups were normalized to the mean levels in wild-type, control whole kidneys (WT nSTZ-ND group), 
and expressed in arbitrary units. Data are means±SEM. n=4-11. *p<0.05 vs. nSTZ-ND, #p< 0.05 vs. nSTZ-HFD, †p< 0.05 vs. STZ-ND. Two symbols, p<0.01; three symbols, p<0.001.  
 
Gene name 







WT   
STZ-HFD 








Pro-inflammatory gene                 
Mcp1 1.0±0.1 1.1±0.1 7.6±1.3* 14.1±2.0**##† 1.1±0.2 0.6±0.1 4.1±0.4*** 9.0±1.4**#† 
F4/80 1.0±0.2 1.2±0.1 1.6±0.4 3.8±0.6*#† 0.3±0.1 0.2±0.1 0.6±0.1* 1.0±0.2*# 
Cd68 1.0±0.1 1.1±0.0 1.8±0.3 3.6±0.6*#† 0.4±0.1 0.4±0.1 0.8±0.1** 1.5±0.3* 
 Tnfa 1.0±0.3 1.0±0.2 1.9±0.5 2.4±0.3*# 0.6±0.1 0.5±0.1 1.4±0.1** 1.7±0.4 
 Pai1 1.0±0.1 0.8±0.1 2.6±0.8 6.5±1.6# 1.1±0.1 0.9±0.2 3.0±0.7* 11.8±4.8 
 Il1b 1.0±0.2 1.4±0.2 0.7±0.2 1.5±0.2† 0.5±0.1 1.3±0.1** 1.1±0.2* 2.1±0.7 
ECM-associated gene            
Tgfb1 1.0±0.0 1.1±0.0 1.2±0.1 1.6±0.1*† 0.9±0.1 0.9±0.1 1.6±0.1*** 2.4±0.3* 
 Fn 1.0±0.6 0.9±0.1 1.7±0.3 2.7±0.5*# 0.3±0.0 0.3±0.0 0.9±0.1*** 1.7±0.6 
 Col4a3 1.0±0.0 1.2±0.0** 0.6±0.1** 0.9±0.1##† 1.5±0.1 1.6±0.1 1.8±0.1 2.4±0.4 
 Ctgf 1.0±0.1 0.8±0.1 0.9±0.0 1.0±0.2 1.3±0.1 0.9±0.1* 1.5±0.1 2.4±0.5 
 Mmp2 1.0±0.1 1.1±0.1 2.9±0.3** 5.6±1.1*# 1.0±0.2 1.0±0.2 2.6±0.2** 6.9±2.1 
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Toll-like receptors          
toll-like receptor 4 Tlr4 12.2 30.1 51.9 13.2 76.3 2.5 1.7 5.8 
toll-like receptor 1 Tlr1 17.4 9.3 0.5 5.8 13.9 0.5 0.1 2.4 
toll-like receptor 2 Tlr2 18.6 18.5 19.0 6.9 39.3 1.0 1.0 5.7 
toll-like receptor 3 Tlr3 66.1 39.7 49.9 60.0 51.5 0.6 1.3 0.9 
toll-like receptor 5 Tlr5 2.2 7.1 19.2 15.3 21.0 3.2 2.7 1.4 
toll-like receptor 6 Tlr6 4.4 8.3 7.6 16.8 13.5 1.9 0.9 0.8 
toll-like receptor 7 Tlr7 4.4 3.3 1.1 1.9 1.9 0.8 0.3 1.0 
toll-like receptor 8 Tlr8 2.0 2.3 7.6 13.9 1.6 1.2 3.3 0.1 
toll-like receptor 9 Tlr9 16.2 17.9 20.0 8.1 17.3 1.1 1.1 2.1 
toll-like receptor 12 Tlr12 17.7 15.9 15.1 11.1 20.3 0.9 0.9 1.8 
toll-like receptor 13 Tlr13 15.6 2.6 16.2 3.9 10.3 0.2 6.2 2.6 
Endogenous ligands of TLR4          
myeloid-related protein 8 S100a8 10.5 31.2 73.2 13.1 43.2 3.0 2.3 3.3 
myeloid-related protein 14 S100a9 11.5 27.7 66.5 7.0 52.1 2.4 2.4 7.4 
serum amyloid A 3 Saa3 14.6 6.5 20.5 16.9 11.0 0.4 3.2 0.7 
high mobility group box 1 Hmgb1 992.9 903.4 831.4 1375.7 1301.4 0.9 0.9 0.9 
biglycan Bgn 972.7 366.9 484.2 215.2 461.1 0.4 1.3 2.1 
heat shock protein 1A (HSP70) Hspa1a 184.6 125.8 84.2 395.9 1612.1 0.7 0.7 4.1 
heat shock protein 1 
(chaperonin 10, HSP60) Hspe1 409.3 449.3 303.8 343.5 474.8 1.1 0.7 1.4 
heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
Hsp90 
ab1 
2090.3 2252.6 1534.1 2395.6 2928.7 1.1 0.7 1.2 
hyaluronan synthase 2 Has2 4.2 8.2 3.0 1.1 5.6 2.0 0.4 5.1 
hyaluronan synthase 3 Has3 9.7 0.6 0.8 1.3 0.8 0.1 1.3 0.6 
hyaluronan synthase1 Has1 14.7 2.1 21.2 11.5 4.4 0.1 10.1 0.4 
perlecan Hspg2 52.5 35.5 48.1 25.3 39.0 0.7 1.4 1.5 
syndecan 2 Sdc2 254.0 451.3 181.1 959.7 726.2 1.8 0.4 0.8 
defensin beta 2 Defb2 2.2 2.6 8.0 2.4 0.9 1.2 3.1 0.4 
elastase 2 Ela2 6.7 11.6 16.4 1.9 3.3 1.7 1.4 1.7 
ECM-associated genes          
Transforming growth factor, 
beta 1 
Tgfb1 10.2 13.8 23.2 14.5 23.5 1.4 1.7 1.6 
fibronectin 1 Fn1 232.8 87.5 117.5 91.9 135.7 0.4 1.3 1.5 
procollagen, type IV, alpha 1 Col4a1 349.3 266.1 384.4 332.5 583.6 0.8 1.4 1.8 
procollagen, type IV, alpha 3 Col4a3 550.5 409.1 904.2 193.2 560.7 0.7 2.2 2.9 
procollagen, type I, alpha 1 Col1a1 152.0 15.5 49.0 23.2 15.3 0.1 3.2 0.7 
connective tissue growth factor Ctgf 928.4 788.0 1245.4 475.9 4427.1 0.8 1.6 9.3 
matrix metalloproteinase 2 Mmp2 40.7 25.2 51.9 26.0 120.2 0.6 2.1 4.6 
Pro-inflammatory genes          
chemokine (C-C motif) ligand 2 Ccl2 0.8 2.3 22.5 12.5 19.8 2.9 9.8 1.6 
chemokine (C-C motif) receptor 2 Ccr2 20.4 17.0 39.2 10.5 16.3 0.8 2.3 1.6 
EGF-like module containing, 
mucin-like, hormone 
receptor-like sequence 1 
Emr1 72.8 40.5 47.4 16.7 21.1 0.6 1.2 1.3 
CD68 antigen Cd68 28.2 11.3 13.2 9.0 29.2 0.4 1.2 3.2 
tumor necrosis factor Tnf 0.9 2.3 8.9 2.3 11.5 2.6 3.9 5.0 
interleukin 1 beta Il1b 19.0 15.1 24.2 9.6 25.0 0.8 1.6 2.6 
interleukin 6 Il6 6.2 2.2 6.0 0.2 6.2 0.4 2.7 31.0 
chemokine (C-C motif) ligand 
5 (RANTES) Ccl5 15.8 7.0 3.8 1.3 4.8 0.4 0.5 3.7 
chemokine (C-X-C motif) 
ligand 10 
Cxcl10 15.4 40.1 76.3 31.4 34.7 2.6 1.9 1.1 
advanced glycosylation end 
product-specific receptor 
Ager 14.4 30.8 15.6 5.0 2.7 2.1 0.5 0.5 
          
 (Legend for ESM Table 4) 
Gene expression levels in control non-STZ C57BL/6J whole kidney (control B6 wk) are shown as 
references. Relative expression levels of control non-STZ glomeruli vs. whole kidney (B6 Glom/Wk 
raio), STZ vs. non-STZ glomeruli (STZ/non-STZ raio) and A-ZIP/F-1 vs. FVB-N glomeruli 
(A-ZIP/FVB-N ratio) are also shown. Of note, the numbers indicate signal intensities of respective 




 ESM Table 5 
PCR Array analysis of genes 
involved in TLR-downstream 
signaling cascade in kidneys of 
WT and Tlr4 KO mice treated 
with STZ and/or HFD 
 
Data are expressed as fold changes 
from nSTZ-ND control.  
Asterisk indicates efficient 














Toll-like receptor 1 Tlr1 3.0 3.4 3.1 3.0
Toll-like receptor 2 Tlr2 2.4 5.8 6.7 5.4
Toll-like receptor 3 Tlr3 1.6 1.4 1.1 0.9
Toll-like receptor 4 Tlr4 2.9 5.1 0.0* 0.0*
Toll-like receptor 5 Tlr5 2.6 2.9 3.4 5.3
Toll-like receptor 6 Tlr6 4.3 3.7 2.8 2.2
Toll-like receptor 7 Tlr7 2.3 3.9 2.6 2.2
Toll-like receptor 8 Tlr8 2.7 7.5 4.3 3.0
Toll-like receptor 9 Tlr9 1.7 2.1 2.9 2.3
Mucin 13, epithelial transmembrane Muc13 7.8 18.0 5.9 6.3
Adaptors and TLR interacting proteins
Bruton agammaglobulinemia tyrosine kinase Btk 2.4 3.1 2.4 1.8
CD14 antigen Cd14 5.5 4.4 4.7 3.9
High mobility group box 1 Hmgb1 0.9 0.9 0.8 0.7
Harvey rat sarcoma virus oncogene 1 Hras1 0.7 0.7 1.4 1.4
Heat shock protein 1A Hspa1a 1.1 0.5 0.5 0.4
Heat shock protein 1 (chaperonin) Hspd1 0.6 0.8 0.6 0.7
Lymphocyte antigen 86　（MD-1) Ly86 2.0 3.1 1.5 3.5
Lymphocyte antigen 96 (MD-2) Ly96 1.5 1.4 1.1 1.0
Mitogen-activated protein kinase 8 interacting protein 3 (JIP3) Mapk8ip3 1.0 1.0 1.3 1.2
Myeloid differentiation primary response gene 88 Myd88 2.9 2.0 1.1 0.9
Pellino 1 Peli1 1.3 1.5 1.0 0.8
Peptidoglycan recognition protein 1 Pglyrp1 8.1 4.8 2.3 2.1
Receptor (TNFRSF)-interacting serine-threonine kinase 2 Ripk2 1.7 1.8 1.3 1.2
Toll-like receptor adaptor molecule 1 Ticam1 0.7 0.4 0.8 0.7
Toll-like receptor adaptor molecule 2 Ticam2 3.1 4.8 8.7 5.7
Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein Tirap 1.3 1.4 1.5 1.2
Toll interacting protein Tollip 0.8 0.7 0.9 0.8
Effectors
Caspase 8 Casp8 1.5 1.2 0.9 0.9
Fas (TNFRSF6)-associated via death domain Fadd 1.0 0.6 0.9 1.0
Interleukin-1 receptor-associated kinase 1 Irak1 1.4 1.1 1.0 1.0
Interleukin-1 receptor-associated kinase 2 Irak2 0.9 0.8 1.0 0.9
Mitogen-activated protein kinase kinase kinase 7 Map3k7 1.5 1.4 1.0 1.0
Nuclear receptor subfamily 2, group C, member 2 (TAK1) Nr2c2 1.2 0.9 1.0 0.9
Peroxisome proliferator activated receptor alpha Ppara 0.7 0.9 0.4 0.5
Eukaryotic translation initiation factor 2-alpha kinase 2 Eif2ak2 1.8 2.1 1.7 1.5
Tnf receptor-associated factor 6 Traf6 1.3 1.0 0.8 0.8
Ubiquitin-conjugating enzyme E2N Ube2n 1.2 1.2 0.8 0.8
Ubiquitin-conjugating enzyme E2 variant 1 Ube2v1 0.9 0.8 1.1 1.2
Downstream pathways and target genes
    NFκB pathway
Chemokine (C-C motif) ligand 2 (MCP-1) Ccl2 9.6 24.8 11.5 8.0
Conserved helix-loop-helix ubiquitous kinase　(IKKa) Chuk 0.8 1.3 0.6 0.7
Colony stimulating factor 2 (granulocyte-macrophage) (GM-CSF) Csf2 20.7 20.2 8.1 6.3
Colony stimulating factor 3 (granulocyte) (G-CSF) Csf3 6.8 2.3 0.8 1.0
Interferon beta 1, fibroblast Ifnb1 2.2 5.4 1.2 1.6
Interferon gamma Ifng 3.2 2.4 1.7 1.9
Inhibitor of kappaB kinase beta　(IKKb) Ikbkb 1.0 1.0 0.8 0.9
Interleukin 1 alpha Il1a 1.1 1.3 1.6 2.2
Interleukin 1 beta Il1b 1.4 2.3 2.9 2.5
Interleukin 1 receptor, type I Il1r1 2.6 1.9 1.8 1.4
Interleukin 2 Il2 13.4 27.7 2.3 2.2
Interleukin 6 Il6 4.8 6.4 8.9 7.7
Interleukin 10 Il10 79.0 47.6 4.4 3.8
Interleukin 12A Il12a 1.1 1.6 2.7 4.0
Lymphotoxin A　(TNFb) Lta 2.3 1.1 2.3 2.8
Mitogen-activated protein kinase kinase kinase 1 (MEKK1) Map3k1 1.4 1.3 1.2 1.0
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,
p105 Nfkb1 1.6 1.5 1.7 1.4
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2,
p49/p100 Nfkb2 1.7 1.7 2.8 2.7
Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha Nfkbia 2.5 3.5 1.1 1.5
Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, beta Nfkbib 3.3 2.3 1.5 1.5
Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor-like 1 Nfkbil1 1.9 1.4 0.9 0.9
Nuclear factor related to kappa B binding protein Nfrkb 1.1 0.9 0.9 0.9
Reticuloendotheliosis oncogene Rel 1.7 1.9 1.2 1.4
V-rel reticuloendotheliosis viral oncogene homolog A (avian) Rela 1.3 1.2 1.5 1.3
Tumor necrosis factor (TNFa) Tnf 9.3 4.3 3.6 2.9
Tumor necrosis factor, alpha-induced protein 3 Tnfaip3 2.3 3.3 2.5 2.5
Tumor necrosis factor receptor superfamily, member 1a Tnfrsf1a 1.2 1.1 1.8 1.6
TNFRSF1A-associated via death domain Tradd 1.0 1.0 1.2 1.2
    JNK/p38 pathway
ELK1, member of ETS oncogene family Elk1 2.8 1.9 0.7 0.7
FBJ osteosarcoma oncogene Fos 1.7 1.5 4.8 1.6
Jun oncogene Jun 0.9 1.3 1.5 1.4
Mitogen-activated protein kinase kinase 3 (MKK3) Map2k3 1.6 1.4 1.0 1.1
Mitogen-activated protein kinase kinase 4 (MKK4) Map2k4 1.5 1.4 1.0 1.0
Mitogen-activated protein kinase kinase kinase 1 (MEKK1) Map3k1 1.4 1.3 1.2 1.0
Mitogen-activated protein kinase 8 (JNK1) Mapk8 1.2 1.1 0.5 0.6
Mitogen-activated protein kinase 9 (JNK2) Mapk9 1.2 1.1 0.9 0.7
    NF/IL6 pathway
CCAAT/enhancer binding protein (C/EBP), beta Cebpb 1.8 2.9 1.2 1.8
C-type lectin domain family 4, member e Clec4e 1.4 3.0 2.0 2.3
Interleukin 6 receptor, alpha Il6ra 1.3 1.3 1.9 1.4
Prostaglandin-endoperoxide synthase 2 (Cox-2) Ptgs2 6.9 5.2 3.0 1.5
    IRF pathway
Chemokine (C-X-C motif) ligand 10 (IP-10) Cxcl10 5.0 9.7 3.4 3.5
Interferon beta 1, fibroblast Ifnb1 2.2 5.4 1.2 1.6
Interferon regulatory factor 1 Irf1 2.4 2.0 1.8 1.7
Interferon regulatory factor 3 Irf3 1.4 0.7 0.9 0.9
TANK-binding kinase 1 Tbk1 1.0 0.9 0.8 0.8
Regulation of adaptive immunity
CD80 antigen Cd80 9.9 17.6 6.5 5.9
CD86 antigen Cd86 2.8 3.6 3.4 3.2
Receptor (TNFRSF)-interacting serine-threonine kinase 2 Ripk2 1.7 1.8 1.3 1.2
Tnf receptor-associated factor 6 Traf6 1.3 1.0 0.8 0.8

















ESM Fig. 1 
Treatment of db/db mice with high fat diet (HFD) exacerbates albuminuria. Data are means±SEM. 





















ESM Fig. 2 
Renal interstitial macrophage infiltration is markedly enhanced in WT mice co-treated with STZ and 
HFD, but not in Tlr4 KO mice. Interstitial macrophage number per 20 high power fields (HPF). 
Magnification, 20x. White bars, WT; black bars, KO. n=4-5. *p<0.05, **p<0.01. ***p<0.001. 





ESM Fig. 3 
Gene expression levels of (a) Tlr4 and (b) S100a8 are elevated in glomeruli of two different types of 
diabetic mice by real-time RT-PCR. (c) Neither diabetes nor (d) HFD treatment causes upregulation 
of Hmgb1 (encoding high mobility group box 1) expression in mouse glomeruli. Data are 






ESM Fig. 4 
Interstitial expression of Tlr4, S100a8 and S100a9 mRNA is not altered in WT and Tlr4 KO mice 
co-treated with STZ and HFD. Gene expressions of Tlr4, S100a8 and S100a9 in whole kidney and 
glomerulus determined by real-time RT-PCR are presented for comparison. Data are means±SEM. 






















ESM Fig. 5 
Co-treatment by STZ and HFD causes markedly increased number of S100a8-positive cells in WT 
but not in Tlr4 KO glomeruli. Data are means±SEM. n=4-6. *p< 0.05, $p< 0.05 for similarly treated 




ESM Fig. 6 
Gene expression levels of Cd36 and Srebp1c in the kidney and S100a8 in the liver and aorta by 
real-time RT-PCR in mice treated with STZ and/or HFD. Upregulation in (a) Cd36 or (b) Srebp1c 
expression in glomeruli does not explain synergistic effects of STZ and HFD upon renal injury. 
Organs were collected at ad libitum feeding conditions. Data are means±SEM. n=4-11. (c) Treatment 
of STZ mice with HFD results in a tendency of increased S100a8 expression in the liver and aorta. 
n=3. *p<0.05, **p<0.01, ***p<0.001. 
 
